SVNS — Solvonis Therapeutics Share News
0.000.00%
Last trade - 00:00Solvonis Therapeutic - Announces Positive Bridging Data Supporting
Solvonis Therapeutic - Notice of Annual General Meeting
RCS - Solvonis Therapeutic - CSO Speaks at National Research Meeting
Solvonis Therapeutic - Final Results
RCS - Solvonis Therapeutic - Appointment of Water Tower Research
RCS - Solvonis Therapeutic - US CNS Executive Order
Brief: Solvonis Therapeutics Says SVN-114 Selected As Lead Candidate For PTSD Discovery Programme
Solvonis Therapeutic - Research and Development Update – Q4 2025
Brief: Solvonis Therapeutics Says NIDA To Fund Early Preclinical Evaluation Of Svn-015
Brief: Solvonis Therapeutics Completes Corporate Restructuring Actions
Solvonis Therapeutic - Appoints global biopharma leader Paul Carter
Solvonis Therapeutic - Raises £1.25 Million to Accelerate Programmes
Solvonis Therapeutic - Half-year Report
Solvonis Therapeutic - Solvonis secures exclusive CNS collaboration
RCS - Solvonis Therapeutic - Media Coverage: Small Cap Idea profile
Solvonis Therapeutic - SVN-SDN-14 PTSD - Positive pre-clinical results
Brief: Solvonis Therapeutics Initiates Studies For SVN-002 To Support 505(B)(2) Pathway And Advance Towards Phase 2B Trial
Solvonis Therapeutic - Translational Bridging Studies
Solvonis Therapeutic - Exercise of warrants